Human LILRB1 ELISA Kit | LILRB1 elisa kit

Human LILRB1 ELISA Kit

Cat. Num. AAA1753900

• Gene Names: LILRB1; ILT2; LIR1; MIR7; CD85J; ILT-2; LIR-1; MIR-7
• Reactivity: Human
• Synonyms: LILRB1; Human LILRB1 ELISA Kit; Leukocyte immunoglobulin-like receptor subfamily B member 1; LIR-1; Leukocyte immunoglobulin-like receptor 1; CD85 antigen-like family member J; Immunoglobulin-like transcript 2; ILT-2; Monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j; ILT2; LIR1; MIR7; leukocyte immunoglobulin like receptor B1; LILRB1 elisa kit

• Reactivity: Human
• Specificity: Natural and recombinant human LILRB1

• Samples: cell culture supernatants, serum and plasma (heparin, EDTA, citrate)
• Detection Range: 312pg/ml-20,000pg/ml
• Sensitivity: <50pg/ml
• Capture/Detection Antibodies: Capture antibody- a monoclonal antibody from mouse|Detection antibody- a biotinylated polyclonal antibody from goat
• Sample Data: Concentration(pg/ml)|0|312|625|1250|2500|5000|10000|20000; O.D.|0.062|0.144|0.218|0.378|0.612|0.939|1.446|2.059
• Intra-Assay Precision: Sample|1|2|3|; n|16|16|16|; Mean(pg/ml)|364|2379|7370|; Standard deviation|18.93|126.09|405.35|; CV(%)|5.2%|5.3%|5.5%|
• Inter-Assay Precision: Sample|1|2|3|; n|24|24|24; Mean(pg/ml)|417|2441|8736; Standard deviation|25.44|156.22|585.31; CV(%)|6.1%|6.4%|6.7%
• Reproducibility: To assay reproducibility, three samples with differing target protein concentrations were assayed using four different lots.; Lots: Lot 1 (pg/ml)|Lot 2 (pg/ml)|Lot 3 (pg/ml)|Lot 4 (pg/ml)|Mean (pg/ml)|Standard Deviation|CV (%); Sample 1: 364|349|378|353|361|11.24|3.1%; Sample 2: 2379|2185|2390|2124|2269|117.06|5.1%; Sample 3: 7370|7573|8346|7810|7774|364.72|4.6%; *number of samples for each test n=16.
• Cross Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Immunogen: Expression system for standard: NS0; Immunogen sequence: G24-V461
• Anticoagulant: heparin, EDTA or citrate
• Principle: Human LILRB1 ELISA Kit is based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for LILRB1 has been precoated onto 96-well plates. Standards(Expression system for standard: NS0, Immunogen sequence: G24-V461) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for LILRB1 is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex is added and unbound conjugates are washed away with PBS or TBS buffer. HRP substrate TMB are used to visualize HRP enzymatic reaction. TMB is catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human LILRB1 amount of sample captured in plate.
• Assay Procedure Step 1: Aliquot 0.1ml per well of the 20000pg/ml, 10000pg/ml, 5000pg/ml, 2500pg/ml, 1250pg/ml, 625pg/ml, 312pg/ml human LILRB1 standard solutions into the precoated 96-well plate. Add 0.1ml of the sample diluent buffer into the control well (Zero well). Add 0.1ml of each properly diluted sample of human cell culture supernatants, serum or plasma (heparin, EDTA, citrate) to each empty well. See "Sample Dilution Guideline" for details. We recommended that each human LILRB1 standard solution and each sample be measured in duplicate.
• TMB Incubation Time: 15-20
• Preparation and Storage: Store at 4 degree C for 6 months, at -20 degree C for 12 months. Avoid multiple freeze-thaw cycles. (Shipped with wet ice.)

Typical Testing Data/Standard Curve (for reference only)

(Human LILRB1 ELISA Kit Standard Curve)

Related Product Information for LILRB1 elisa kit

Leukocyte immunoglobulin-like receptors (LILRs), also called CD85s, ILTs, or LIRs, are important mediators of immune activation and tolerance that contain tandem immunoglobulin (Ig)-like folds. LILRB1 is encoded within the leukocyte receptor complex on 19q13. 4, previously implicated to be a susceptibility region to systemic lupus erythematosus (SLE). LILRB1 binds to a wide range of major histocompatibility complex class I molecules (MHCIs) and transduces negative signals that can, for example, prevent killing of MHCI-expressing cells. LILRB1 transcription is correlated with surface protein expression on NK cells.

Product Categories/Family for LILRB1 elisa kit

ELISA kits

NCBI and Uniprot Product Information

• NCBI GI #: 612149795
• NCBI GeneID: 10859
• NCBI Accession #: NP_001075108.2
• NCBI GenBank Nucleotide #: NM_001081639.3
• UniProt Accession #: Q8NHL6; O75024; O75025; Q8NHJ9; Q8NHK0; A2IXV4; A8MXT0
• Molecular Weight: 70,819 Da
• NCBI Official Full Name: leukocyte immunoglobulin-like receptor subfamily B member 1 isoform 4
• NCBI Official Synonym Full Names: leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
• NCBI Official Symbol: LILRB1
• NCBI Official Synonym Symbols: ILT2; LIR1; MIR7; CD85J; ILT-2; LIR-1; MIR-7
• NCBI Protein Information: leukocyte immunoglobulin-like receptor subfamily B member 1; Ig-like transcript 2; CD85 antigen-like family member J; monocyte/macrophage immunoglobulin-like receptor 7; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform
• UniProt Protein Name: Leukocyte immunoglobulin-like receptor subfamily B member 1
• Protein Family: Leukocyte immunoglobulin-like receptor subfamily
• UniProt Gene Name: LILRB1
• UniProt Synonym Gene Names: ILT2; LIR1; MIR7; LIR-1; Leukocyte immunoglobulin-like receptor 1; ILT-2; MIR-7
• UniProt Entry Name: LIRB1_HUMAN

NCBI Description

This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Description

LILRB1: Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral; Receptor, misc.

Chromosomal Location of Human Ortholog: 19q13.4

Cellular Component: cytoplasm; extracellular region; plasma membrane; integral to membrane; external side of plasma membrane

Molecular Function: protein homodimerization activity; MHC class I receptor activity; MHC class I protein binding; HLA-A specific inhibitory MHC class I receptor activity; SH2 domain binding; HLA-B specific inhibitory MHC class I receptor activity; protein phosphatase 1 binding

Biological Process: immune response-inhibiting cell surface receptor signaling pathway; regulation of immune response; negative regulation of calcium ion transport; negative regulation of mononuclear cell proliferation; positive regulation of apoptosis; negative regulation of endocytosis; response to virus; negative regulation of natural killer cell mediated cytotoxicity; signal transduction; negative regulation of cytokine secretion during immune response; negative regulation of interferon-gamma biosynthetic process; negative regulation of cell cycle; negative regulation of serotonin secretion; negative regulation of alpha-beta T cell activation; negative regulation of T cell proliferation; T cell proliferation during immune response; receptor internalization; negative regulation of interferon-gamma production; negative regulation of T cell mediated cytotoxicity; interferon-gamma production; negative regulation of tumor necrosis factor biosynthetic process; Fc receptor mediated inhibitory signaling pathway; positive regulation of cytolysis; positive regulation of transcription from RNA polymerase II promoter; positive regulation of defense response to virus by host; defense response to virus